hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06381843, orgStudyIdInfo id: WSKCT004, briefTitle: A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-08-02, primaryCompletionDateStruct date: 2023-03-29, completionDateStruct date: 2023-12-30, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: WestVac Biopharma Co., Ltd., class: INDUSTRY, collaborators name: West China Hospital, descriptionModule briefSummary: A observer-blind, randomized, controlled, investigator-initiated clinical trial to evaluate the safety and immunogenicity of a booster vaccination with Recombinant COVID-19 vaccine (Sf9 Cell) in a population aged 18-60 years old who have completed 3 doses vaccination with COVID-19 Vaccine (Vero Cell), Inactivated ≥ 6 months at least 6 months prior to enrolment. The study uses a non-inferiority design to compare between schedules with Recombinant COVID-19 Vaccine (Sf9 Cell) versus COVID-19 Vaccine (Vero Cell) Inactivated as the booster dose. Participants, laboratory and analysing statisticians will remain blind to treatment allocation.A total of 120 participants will be enrolled, participants will be randomized 1:1 to receive a single dose of Recombinant COVID-19 vaccine (Sf9 Cell) (test group) or COVID-19 Vaccine (Vero Cell), Inactivated., conditionsModule conditions: COVID-19, conditions: SARS-CoV-2 Infection, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 120, type: ACTUAL, armsInterventionsModule interventions name: Recombinant COVID-19 Vaccine (Sf9 Cell), interventions name: COVID-19 Vaccine (Vero Cell), Inactivated, outcomesModule primaryOutcomes measure: Incidence of adverse drug reactions (ADRs), primaryOutcomes measure: Geometric mean titer (GMT) of specific neutralizing antibody against SARS-CoV-2 prototype strain, primaryOutcomes measure: Geometric mean titer (GMT) of specific neutralizing antibody against SARS-CoV-2 Omicron variant, secondaryOutcomes measure: Geometric mean increase (GMI) of specific neutralizing antibody against SARS-CoV-2 prototype strain, secondaryOutcomes measure: Geometric mean increase (GMI) of specific neutralizing antibody against SARS-CoV-2 Omicron variant, secondaryOutcomes measure: GMT and GMI of specific neutralizing antibody against SARS-CoV-2 prototype strain, secondaryOutcomes measure: GMT and GMI of specific neutralizing antibody against SARS-CoV-2 omicron variant, secondaryOutcomes measure: GMT and GMI of IgG antibodies against SARS-CoV-2 S protein RBD, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: West China Hospital of Sichuan University, city: Chengdu, state: Sichuan, country: China, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06381830, orgStudyIdInfo id: ASCT+CART, briefTitle: Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2027-01-01, completionDateStruct date: 2027-01-01, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital of Soochow University, class: OTHER, collaborators name: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, collaborators name: Suzhou Hongci Hematology Hospital, Suzhou, China, descriptionModule briefSummary: The study is designed to evaluate the efficacy and safety of chimeric antigen receptor T-cell therapy following autologous stem cell transplantation for relapsed/refractory B-cell Non-Hodgkin's lymphoma., conditionsModule conditions: Lymphoma, B-Cell, conditions: Autologous Stem Cell Transplantation, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: Apheresis, interventions name: Autologous Stem Cell Transplantation, interventions name: CAR-T Cell Therapy, outcomesModule primaryOutcomes measure: Overall Response Rate (ORR), primaryOutcomes measure: Progression-free Survival（PFS）, secondaryOutcomes measure: Duration of Response(DOR), secondaryOutcomes measure: Complete Response Rate, secondaryOutcomes measure: Overall Survival（OS）, secondaryOutcomes measure: Adverse events profile, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Soochow University, status: RECRUITING, city: Suzhou, state: Jiangsu, zip: 215000, country: China, contacts name: Caixia Li, M.D., role: CONTACT, phone: +86 512 67781856, email: licaixia@suda.edu.cn, geoPoint lat: 31.30408, lon: 120.59538, hasResults: False
protocolSection identificationModule nctId: NCT06381817, orgStudyIdInfo id: 2024112, briefTitle: Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2028-03-31, completionDateStruct date: 2028-03-31, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital of Soochow University, class: OTHER, collaborators name: Children's Hospital of Soochow University, collaborators name: Ruijin Hospital, collaborators name: Nanfang Hospital, Southern Medical University, collaborators name: Fujian Medical University Union Hospital, collaborators name: First Affiliated Hospital Xi'an Jiaotong University, collaborators name: Wuhan Union Hospital, China, collaborators name: Zhejiang University, descriptionModule briefSummary: The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL). It will also learn about the safety of the transplantation. The main questions it aims to answer are:Dose co-infusion of cord blood in haploidentical hematopoietic cell transplantation (haplo-HCT) lower the rate of relapse? What medical problems do participants have when having haplo-cord HCT? Researchers will compare haplo-cord HCT to haplo-HCT to see if haplo-cord HCT works to treat T-ALL.Participants will be infused an unrelated cord blood unit at the same day of haploidentical graft infusion., conditionsModule conditions: Acute T Cell Lymphoblastic Leukemia, conditions: Haploidentical Hematopoietic Stem Cell Transplantation, conditions: Cord Blood, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 146, type: ESTIMATED, armsInterventionsModule interventions name: Haplo-cord HCT, interventions name: Haplo-HCT, outcomesModule primaryOutcomes measure: Progression-free survival, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Cumulative incidence of relapse, secondaryOutcomes measure: Non-relapse mortality, secondaryOutcomes measure: Adverse events, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Soochow University, status: RECRUITING, city: Suzhou, state: Jiangsu, zip: 215000, country: China, contacts name: Yang XU, role: CONTACT, phone: 86+051267781850, email: xuyang1020@126.com, contacts name: Yang Xu, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.30408, lon: 120.59538, hasResults: False
protocolSection identificationModule nctId: NCT06381804, orgStudyIdInfo id: 24YL9001, briefTitle: Effect of Shotblocker and Palm Stimulator, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-19, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Necmettin Erbakan University, class: OTHER, descriptionModule briefSummary: This study discusses the advancements in nursing, particularly focusing on intramuscular injections, their complications, and innovative non-pharmacological methods such as the Shotblocker and palm stimulator to reduce pain. These methods, based on the gate control theory, aim to minimize discomfort during injections by applying tactile stimulation, which has proven effective in various studies., conditionsModule conditions: Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 96, type: ESTIMATED, armsInterventionsModule interventions name: shotblocker, interventions name: palm stimulator, outcomesModule primaryOutcomes measure: Visual analog scale (VAS) pain Scale score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Necmettin Erbakan University, status: RECRUITING, city: Meram, country: Turkey, contacts name: Gülden Basit, role: CONTACT, phone: (0 332) 320 40 29, email: guldenbasit@gmail.com, contacts role: CONTACT, phone: (0 332) 320 40 29, contacts name: Merve Öz, role: SUB_INVESTIGATOR, geoPoint lat: 37.82985, lon: 32.46777, hasResults: False
protocolSection identificationModule nctId: NCT06381791, orgStudyIdInfo id: PRO00036811, briefTitle: CBD for Pain Following Orthopedic Shoulder Surgery, acronym: CBD, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-12-30, completionDateStruct date: 2027-12-30, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: The Methodist Hospital Research Institute, class: OTHER, descriptionModule briefSummary: The goal of the study is to learn if Epidiolex (cannabidiol) works as a additional pain medication in patients who have had orthopedic shoulder surgery. It is also to learn about safe dosages and identify any side effects after surgery.Researchers will compare Epidiolex to a placebo solution to see if Epidiolex lowers pain after shoulder surgery.Participants will:* track their pain and what medications they use every day in a provided pain diary. A researchers will call every seven days to check on the participant and diary.* Complete two short surveys. Once before surgery and once after.* Have bloodwork tested after surgery, conditionsModule conditions: Shoulder Osteoarthritis, conditions: Rotator Cuff Injuries, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This study is designed as a randomized, double-blinded controlled trial. Patients will be recruited in clinic preoperatively prior to their scheduled procedure. Patients and the treating physician/research study team will be blinded to the treatment arm. Patients will be randomized to either the test group, which will be prescribed Epidiolex (cannabidiol) postoperatively in addition to the standard pain regimen, or the control group, which will have a placebo provided in addition to the standard pain regimen., primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Epidiolex, interventions name: Placebo oral solution, outcomesModule primaryOutcomes measure: Primary - Pain Journal, secondaryOutcomes measure: Survey Data, secondaryOutcomes measure: Pain Disability Index (PDI), secondaryOutcomes measure: Pain, Enjoyment, General Activity (PEG) Scale, secondaryOutcomes measure: Patient Health Questionnaire 4 (PHQ-4): The four-item patient health questionnaire for anxiety, secondaryOutcomes measure: Pittsburgh Sleep Quality Index (PSQI), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Houston Methodist Hospital, status: RECRUITING, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Haley M Goble, MHA, CRCC, role: CONTACT, phone: 713-441-3930, email: hmgoble@houstonmethodist.org, contacts name: Patrick C McCulloch, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06381778, orgStudyIdInfo id: 112006-E, briefTitle: Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-02-06, primaryCompletionDateStruct date: 2027-12-01, completionDateStruct date: 2027-12-01, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Far Eastern Memorial Hospital, class: OTHER, descriptionModule briefSummary: Hypertrophic cardiomyopathy (HCM) is hallmarked by the presence of left ventricular hypertrophy (LVH) and may present various symptoms including arrhythmia and heart failure. Mutations in the genes related to sarcomeric proteins and metabolic disorders are known causes of HCM. However, it remains required to further explore the prevalence of HCM in the context of Taiwanese' genetic background. Additionally, certain rare diseases that affect the heart, including Fabry disease, cardiac amyloidosis, may present LVH, which makes precise diagnosis among HCM and these diseases more challenging. In this TSOC multi-center registry, we aim to systematically evaluate the clinical, genetic, biochemical features,prevalence, and possible natural course of HCM and relevant rare diseases such as Fabry disease in Taiwan. In the meanwhile, we may also generate the specific "red-flag" signs of Fabry disease in Taiwan., conditionsModule conditions: Hypertrophic Cardiomyopathy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: OTHER, enrollmentInfo count: 2600, type: ESTIMATED, outcomesModule primaryOutcomes measure: Death, secondaryOutcomes measure: CV death, eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Far Eastern Memorial Hospital, status: RECRUITING, city: New Taipei City, zip: 220, country: Taiwan, contacts name: Yen-Wen Wu, MD, PhD, role: CONTACT, phone: 886-2-8966-7000, phoneExt: 1090, email: wuyw0502@gmail.com, contacts name: Yen-Wen Wu, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 25.01111, lon: 121.44583, hasResults: False
protocolSection identificationModule nctId: NCT06381765, orgStudyIdInfo id: Serratus-Pectointercostal, briefTitle: Serratus Plane Block and Pectointercostal Block, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2024-08-01, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Cukurova University, class: OTHER, descriptionModule briefSummary: ASA I-II female patients aged over 18 who will undergoing breast reduction surgery will recruit to the study. Patients will divide into 2 groups. Deep serratus plane block will perform with 0,25 %bupivacaine 20 ml at the midaxillary 5. rib, bilaterally for Group I. At Group II, deep serratus plane block ( 0,25 %bupivacaine 20 ml) at the midaxillary 5.th rib+ pectointercostal plane block (0,25% bupivacaine 15 ml) at 4-5.th intercostal space will perform bilaterally . General anesthesia with sevoflurane and remifentanil will perform to the all patients. Postoperative pain scores, morphine consumption and complications will record till the 24.th hours., conditionsModule conditions: Postoperative Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Serratus plane bock and pectointercostal block, outcomesModule primaryOutcomes measure: postoperative morphine consumption, primaryOutcomes measure: postoperative visual analog scale scores, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06381752, orgStudyIdInfo id: CPMvsPT, briefTitle: Value of Continuous Passive Motion in Rehabilitation After Total Knee Replacement, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-06-25, primaryCompletionDateStruct date: 2020-03-31, completionDateStruct date: 2020-03-31, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Johannes Gutenberg University Mainz, class: OTHER, descriptionModule briefSummary: Immediate rehabilitation after total knee arthroplasty (TKA) differs in terms of volume, intensity but also type of treatment. Continuous passive motion after TKA is so far only investigated for replacing physiotherapy. This study is conducted to investigate CPM when it partially replaces group physiotherapy in terms of functional and patient-reported outcomes., conditionsModule conditions: Total Knee Arthroplasty, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 175, type: ACTUAL, armsInterventionsModule interventions name: Continuous passive motion, interventions name: standard rehabilitation, outcomesModule primaryOutcomes measure: Staffelstein Score, secondaryOutcomes measure: Oxford Knee Score (OKS), secondaryOutcomes measure: Range of motion (ROM), secondaryOutcomes measure: Visual Analogue Scale (VAS), secondaryOutcomes measure: Return to work, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Universitaetsmedizin der JGU Mainz, city: Mainz, state: Rheinland-Pfalz, zip: 55131, country: Germany, geoPoint lat: 49.98419, lon: 8.2791, hasResults: False
protocolSection identificationModule nctId: NCT06381700, orgStudyIdInfo id: DF CO2405/0014 (P), briefTitle: Effectiveness of MySmile App for Improving the Oral Health of Secondary School Children:, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: University of Malaya, class: OTHER, descriptionModule briefSummary: The goal of this cluster-randomised control trial is to assess the effectiveness of the MySmile app for improving oral health in secondary school children. The main questions it aims to answer are:1. Will the MySmile app be more effective in improving secondary school children's dental plaque and gingival health over and above the existing school dental service (SDS)?2. Will the MySmile app be more effective in improving secondary school children's oral health knowledge, attitudes, and behaviours over and above the existing SDS?3. Is the MySmile app easy to use by secondary school children?4. Is the MySmile app acceptable to use from the perspective of secondary school children?Participants in the intervention group will receive the SDS and MySmile app. The control group will receive SDS only. Therefore the researcher will compare between the intervention and control group in terms of dental plaque, gingival health, oral health knowledge, oral health attitudes and oral health behaviours., conditionsModule conditions: Oral Disease, conditions: Gingival Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 303, type: ESTIMATED, armsInterventionsModule interventions name: MySmile app, interventions name: Control, outcomesModule primaryOutcomes measure: The mean decrement in plaque score will be assessed using the Plaque Control Record developed by O'Leary Drake and Naylor in 1972, primaryOutcomes measure: The mean increment in gingival health will be assessed using Gingival Index developed by Silness and Loe in 1963, secondaryOutcomes measure: The mean increment of oral health knowledge, attitude and practice using validated questionnaires., eligibilityModule sex: ALL, minimumAge: 15 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Muhammad Hamidie bin Saari, city: Kuala Lumpur, state: Wilayah Persukutuan Kuala Lumpur, zip: 50480, country: Malaysia, contacts name: Zamros Yuzadi Mohd Yusof, PHD, role: CONTACT, contacts name: Zamros Yuzadi Mohd Yusof, PHD, role: PRINCIPAL_INVESTIGATOR, contacts name: Marhazlinda Jamaludin, Master, role: PRINCIPAL_INVESTIGATOR, contacts name: Unaizah Hanum Obaidellah, PHD, role: PRINCIPAL_INVESTIGATOR, contacts name: Nazirah Ab Mumin, PHD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 3.1412, lon: 101.68653, hasResults: False